Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2024-09-19 Earnings Release
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Earnings Release Classification · 100% confidence The document is an 'Ad Hoc Announcement' dated September 19, 2024, providing provisional financial results for the half-year and second quarter ended June 30, 2024. Crucially, it states: 'We will issue our Half-Year 2024 Financial Results on September 30, 2024.' This indicates the current document is an early announcement or press release summarizing key figures ahead of the full report release. The content focuses on financial performance highlights (net gain/loss, impact of a business sale) but is not the comprehensive report itself. This structure—an early announcement of financial performance for a shorter period than a year—aligns best with the definition of an Interim/Quarterly Report (IR), or potentially an Earnings Release (ER) if it were quarterly only. Since it explicitly covers the 'half-year' results and is a summary preceding the final release, 'Interim / Quarterly Report' (IR) is the most appropriate classification for the subject matter being announced, even though this specific filing is an announcement of that upcoming report. However, given the content is a summary of financial results for a period shorter than a year, and it is not the final, comprehensive report (which is scheduled for Sept 30), it functions as an Earnings Release (ER) announcing the period's performance highlights. Since the document is a press release announcing financial results for a period shorter than a year (half-year), ER is a strong fit, but IR is the category for the comprehensive report itself. Because this document is an announcement *about* the half-year results, and it is not the full report, it is closest to an Earnings Release (ER) which is the initial announcement of periodical results. If the document were the full report released on Sept 30, it would be IR. As it is the pre-announcement, ER is the best fit among the options for an early financial disclosure. H1 2024
2024-09-19 English
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Investor Presentation Classification · 95% confidence The document is a press release dated September 4, 2024, announcing that the CEO of Addex Therapeutics will be attending and presenting at the H.C. Wainwright 26th Annual Investment Conference in September 2024. It details the availability of a pre-recorded video presentation and opportunities for one-on-one meetings. This type of announcement, focusing on executive participation in investor conferences and providing corporate updates for potential investors, aligns best with the Investor Presentation (IP) category, as it is promotional material intended for investors, even though it is an announcement of attendance rather than the presentation itself. However, given the options, it is an announcement about investor engagement and corporate updates, which is closely related to investor presentations. Since it is an announcement about attending a conference where presentations/updates will occur, and it is not a formal regulatory filing (like 10-K or IR) or a simple earnings release (ER), 'Investor Presentation' (IP) is the most fitting category for the *content type* being promoted, or 'Report Publication Announcement' (RPA) if strictly following the 'announcement vs. report' rule. Given the content is about an upcoming corporate update presentation at a conference, 'IP' captures the essence better than 'RPA' which usually announces the release of a formal report. I will classify it as IP as it is marketing/update material for investors.
2024-09-04 English
FORM 6-K
Regulatory Filings
2024-08-27 English
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Regulatory Filings Classification · 95% confidence The document is titled "Ad Hoc Announcement Pursuant to Art. 53 LR" and details a collaboration update between Addex Therapeutics and Indivior regarding the selection of clinical candidates and associated financial milestones. This type of announcement, which communicates significant business developments, partnership progress, or material corporate news outside of scheduled financial reports, is characteristic of a general regulatory announcement. Since it is not a full Annual Report (10-K), an Earnings Release (ER), an Interim Report (IR), or a specific transaction notice (like DIV or SHA), the most appropriate general category for a material, non-standardized regulatory update is Regulatory Filings (RNS). The document length is moderate (6655 chars), suggesting it is the primary communication, not just a link announcement, thus ruling out RPA based on the 'Menu vs Meal' rule for very short announcements.
2024-08-27 English
GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#7E)
Major Shareholding Notification
2024-08-15 English
GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#6)
Major Shareholding Notification
2024-08-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.